This is a working overview of actin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-14 and is reviewed periodically as new material appears.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
This was followed in 1947 by the widespread introduction of methadone, another structurally unrelated compound with pharmacological properties similar to those of morphine. After World War I, further advances were made in the field of intratracheal anesthesia. Among these were those made by Sir Ivan Whiteside Magill (1888–1986). Working at the Queen's Hospital for Facial and Jaw Injuries in Sidcup with plastic surgeon Sir Harold Gillies (1882–1960) and anesthetist E. Stanley Rowbotham (1890–1979), Magill developed the technique of awake blind nasotracheal intubation. Magill devised a new type of angulated forceps (the Magill forceps) that are still used today to facilitate nasotracheal intubation in a manner that is little changed from Magill's original technique. Other devices invented by Magill include the Magill laryngoscope blade, as well as several apparatuses for the administration of volatile anesthetic agents. The Magill curve of an endotracheal tube is also named for Magill. The first hospital anesthesia department was established at the Massachusetts General Hospital in 1936, under the leadership of Henry K. Beecher (1904–1976). Beecher, who received his training in surgery, had no previous experience in anesthesia. Although initially used to reduce the sequelae of spasticity associated with electroconvulsive therapy for psychiatric disease, curare found use in the operating rooms at Bellvue by E.M. Papper and Stuart Cullen in the 1940s using preparations made by Squibb.
=== Vienna, Frankfurt, and Berlin === During the summer of 1924, the Viennese composer Alban Berg's Three Fragments from Wozzeck premiered in Frankfurt, at which time Adorno introduced himself to Berg and mutually agreed the young philosopher and composer would study with Berg in Vienna. Upon moving to Vienna in February 1925, Adorno immersed himself in the musical culture that had grown up around Schoenberg. In addition to his twice-weekly sessions with Berg, Adorno continued his studies on piano with Eduard Steuermann and befriended the violinist Rudolf Kolisch. In Vienna, he and Berg attended public lectures by the satirist Karl Kraus, and he met Lukács, who had been living in Vienna after the failure of the Hungarian Soviet Republic. Berg, whom Adorno called "my master and teacher," was among the most prescient of his young pupil's early friends:
If some of the fish they had previously eaten is available this can also be tested to confirm the diagnosis. Preventive efforts include not eating reef fish, not eating high-risk fish such as barracuda, and not eating fish liver, roe, or fish heads. The toxins have no taste or smell, and cannot be destroyed by conventional cooking. There is no specific treatment for ciguatera fish poisoning once it occurs. Mannitol may be considered, but the evidence supporting its use is not very strong. Gabapentin or amitriptyline may be used to treat some of the symptoms. In 2017, the United States Centers for Disease Control (CDC) estimated that around 50,000 cases occur globally each year. Other estimates suggest up to 500,000 cases per year. The risk of death from poisoning is less than 1 in 1,000 according to the CDC. It is the most frequent seafood poisoning, and up to 5% of patients may develop chronic symptoms, which are treatable using the protocols for Chronic Inflammatory Response Syndrome (CIRS) It occurs most commonly in the Pacific Ocean, Indian Ocean, and the Caribbean Sea between the latitudes of 35°N and 35°S. The risk of the condition appears to be increasing due to coral reef deterioration and increasing trade in seafood. Descriptions of the condition date back to at least 1511. The current name, introduced in 1787, is of Cuban Spanish origin and originally referred to the gastropod Cittarium pica.
== Disinfection == Burkholderia pseudomallei is susceptible to numerous disinfectants, including benzalkonium chloride, iodine, mercuric chloride, potassium permanganate, 1% sodium hypochlorite, 70% ethanol, 2% glutaraldehyde, and to a lesser extent, phenolic preparations. B. pseudomallei is effectively killed by the commercial disinfectants, Perasafe and Virkon. The microorganism can also be destroyed by heating to above 74 °C for 10 min or by ultraviolet irradiation.
== Horse racing scandals == Show jumping horse killings – from 1975 to 1995, wealthy owners and trainers of show jumping horses conspired to electrocute and otherwise kill over-valued as well as under-performing animals in a 20-year-long scheme to defraud insurance companies. Crimes also committed during this equestrian sports scandal include extortion, mail fraud, animal cruelty and the murder of at least one human being. Fine Cotton/Bold Personality ring-in – a 1984 betting scam in which the conspirators, which included some elite figures in Australian Thoroughbred racing, substituted the far more talented Bold Personality for Fine Cotton in a low-class race. The scheme was discovered immediately after the race and the investigation led to lifetime bans for six individuals and bans of more than a decade for at least two more. 2020 Horse racing doping scam – the scam was revealed in March 2020, when the FBI cracked down several top names in American horse racing. Initially, 27 people (trainers and veterinarians) were charged with doping, which later increased to 29 people.
Sources: en.wikipedia.org
== External links == "The Company Behind 'Female Viagra' Just Raised $20 Million in Funding". Fortune. 4 September 2019. "The Women's Libido Pill Is Back, and So Is the Controversy". Bloomberg. 13 June 2018.
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a family of transcription factor protein complexes that controls transcription of DNA, cytokine production and cell survival. NF-κB is found in almost all animal cell types and is involved in cellular responses to stressful stimuli like cytokines, free radicals, heavy metals, ultraviolet irradiation, oxidized LDL, and bacterial or viral antigens. NF-κB plays a key role in regulating the immune response to infection. Incorrect regulation of NF-κB has been linked to cancer, inflammatory and autoimmune diseases, septic shock, viral infection, and improper immune development. NF-κB has also been implicated in processes of synaptic plasticity and memory.
Bacteria were the first organisms to be genetically modified in the laboratory, due to the relative ease of modifying their chromosomes. This ease made them important tools for the creation of other GMOs. Genes and other genetic information from a wide range of organisms can be added to a plasmid and inserted into bacteria for storage and modification. Bacteria are cheap, easy to grow, clonal, multiply quickly and can be stored at −80 °C almost indefinitely. Once a gene is isolated it can be stored inside the bacteria, providing an unlimited supply for research. A large number of custom plasmids make manipulating DNA extracted from bacteria relatively easy. Their ease of use has made them great tools for scientists looking to study gene function and evolution. The simplest model organisms come from bacteria, with most of our early understanding of molecular biology coming from studying Escherichia coli. Scientists can easily manipulate and combine genes within the bacteria to create novel or disrupted proteins and observe the effect this has on various molecular systems. Researchers have combined the genes from bacteria and archaea, leading to insights on how these two diverged in the past. In the field of synthetic biology, they have been used to test various synthetic approaches, from synthesizing genomes to creating novel nucleotides. Bacteria have been used in the production of food for a long time, and specific strains have been developed and selected for that work on an industrial scale.
== Gene == Alternative splicing results in two transcript variants encoding the same protein. This gene and the gene that encodes ribonuclease, RNase A family, 4 share promoters and 5' exons. Each gene splices to a unique downstream exon that contains its complete coding region.
Amin al-Husayni, as chairman Jamal al-Husayni, as vice-chairman Husayin al-Khalidi Emile al-Ghury Ahmed Hilmi Abd al-Baqi The United Kingdom government called the 1946–47 London Conference on Palestine in an attempt to bring peace to its Mandate territory, which began on 9 September 1946. The conference was boycotted by the AHE as well as the Jewish Agency, but was attending by Arab League states, which argued against any partition.
Sources: en.wikipedia.org
=== Formate dehydrogenase === Some microorganisms utilize selenium in formate dehydrogenase. Formate is produced in large amounts in the hepatic (liver cells) mitochondria of embryonic cells and in cancer cells by the folate cycle. Formate is reversibly oxidized by the enzyme formate dehydrogenase:
== History == The effectiveness of tiratricol was evaluated in two clinical studies in people ranging in age from infants to adults, including an international, multi-center, randomized, placebo-controlled trial (NCT05579327) and a longer-term open-label study. Across both studies, participants treated with tiratricol had reductions in excess thyroid hormone levels in the bloodstream and improvements in cardiovascular and metabolic symptoms impacted by thyroid levels, such as systolic blood pressure and heart rate.
=== Expansion to Asia and Europe === Chick-fil-A CEO Andrew Cathy announced in March 2023 that it planned to open restaurants in Asia and Europe by 2026, and was set to expand to five overseas markets by 2030. The Wall Street Journal reported that it was seeking countries with "stable economies, dense populations, and a demand for chicken".
S2CID 17336375. Wickramasinghe, N. C. (2010). "The astrobiological case for our cosmic ancestry". International Journal of Astrobiology. 9 (2): 119–129. Bibcode:2010IJAsB...9..119W. doi:10.1017/S1473550409990413. S2CID 13978227. Wickramasinghe, N.C.; Wallis, J.; Wallis, D.H.; Schild, R.E.; Gibson, C.H. (2012). "Life-bearing planets in the solar vicinity". Astrophysics and Space Science. 341 (2): 295–9. Bibcode:2012Ap&SS.341..295W. doi:10.1007/s10509-012-1092-8. S2CID 120484953. Chandra Wickramasinghe, A Journey with Fred Hoyle: The Search for Cosmic Life, World Scientific Publishing, 2005, ISBN 981-238-912-1 Janaki Wickramasinghe, Chandra Wickramasinghe and William Napier, Comets and the Origin of Life, World Scientific Publishing, 2009, ISBN 981-256-635-X Chandra Wickramasinghe and Daisaku Ikeda, Space and Eternal Life, Journeyman Press, 1998, ISBN 1-85172-060-X
Colin Campbell Norris (born 12 February 1976) is a British serial killer who was convicted of the murder of four elderly patients and the attempted murders of two others in two hospitals in Leeds, England, in 2002. A police investigation showed Norris to be on duty when five patients fell into sudden hypoglycaemic comas. Suspicions were raised when Norris predicted that healthy Ethel Hall would die at 5:15 am one morning, which is when she went into cardiac arrest, and tests revealed that she had been injected with an extremely high level of man-made insulin. Insulin was missing from the hospital fridge and Norris had last accessed it, only half an hour before Hall fell unconscious. Subsequent investigations would find that the unnatural hypoglycaemic attacks followed him when he was transferred to a second hospital, and hospital records revealed that only he could not be eliminated as a suspect. Detectives believed that Norris was responsible for up to six other suspicious deaths where only he was always present, but a lack of post mortem evidence and other factors meant that investigators and the Crown Prosecution Service could not pursue convictions for these deaths. Doubts were later raised about his conviction by, among others, Vincent Marks, an expert on insulin poisoning, who concluded from his own studies that there was a 1 in 10 chance that each patient's arrest could have happened naturally.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.